 | |
| Clinical data | |
|---|---|
| Pronunciation | (/sɛˈvɛləmər/ or /sɛˈvɛləmɪər/) |
| Trade names | Renagel, Renvela |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601248 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 0% |
| Excretion | Feces 100% |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | [(C3H7N)a+b.(C9H17N2O)c]m where a+b:c = 9:1 |
| Molar mass | variable |
  (what is this?) (verify) | |
Sevelamer, sold under the brand name Renagel among others, is a medication used to treat hyperphosphatemia in chronic kidney disease.[1] In the United Kingdom it is a second line treatment.[2] It is taken by mouth with meals.[1]
Common side effects include abdominal pain, diarrhea, nausea, and constipation.[1] A skin rash may also occur.[2] It works by binding phosphate in the intestines.[1]
Sevelamer was approved for medical use in the United States in 1998.[1] In the United States it costs about 48 USD for 270 tablets of 800 mg as of 2021.[3] This amount in the United Kingdom costs the NHS about £75.[2]
References edit
- ^ a b c d e f g h "Sevelamer Monograph for Professionals". Drugs.com. Archived from the original on 30 November 2020. Retrieved 12 October 2021.
- ^ a b c BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1116. ISBN 978-0-85711-369-6.
{{cite book}}: CS1 maint: date format (link) - ^ "Sevelamer Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 19 January 2021. Retrieved 7 April 2021.